Suttichaimongkol Tanita, Rattananukrom Chitchai, Wongsaensook Arthit, Sawanyawisuth Kittisak, Sukeepaisarnjaroen Wattana
MD, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
MD, PhD, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
Germs. 2021 Sep 29;11(3):403-407. doi: 10.18683/germs.2021.1277. eCollection 2021 Sep.
Hepatitis B virus (HBV) infection is associated with cirrhosis and hepatocellular carcinoma. Vaccination is one aspect of public health policy aimed at eliminating HBV infection. After the implementation of an HBV vaccination program for newborns in Thailand, the estimated residual infection rate was 3.5%. However, that study was conducted in only 5,964 participants in seven provinces and only 22 years after the start of the campaign. This study aimed to evaluate the HBV seroprevalence rate in Thailand in larger sample size and a longer duration after program implementation using HBV surveillance.
This was a surveillance study conducted in 20 provinces in northeast Thailand. The study period was between July 2010 and November 2019. Rates of HBV seroprevalence in each province and overall were calculated. Participants were divided into two groups: those vaccinated under the national campaign and those who were not. Participants aged 0-20 years were used as references, while other age groups (intervals of 10 years) were comparators. Residual HBV seroprevalence after the vaccination program was calculated with odds ratio for HBV seroprevalence in each age group.
There were 31,855 subjects who participated in the project. Of those, 1,805 (5.7%) had HBV. The HBV seroprevalence rate in the national HBV vaccination group was significantly lower than that in those not vaccinated under the national program (1.0% vs 5.9%; p<0.001). Seroprevalence was 1.0% in participants ≤20 years of age. Participants 31-40 years of age had the highest odds ratio (10.41), followed those 21-30 years of age (7.42).
This real-world surveillance study showed that residual HBV infection was 1.0% after nearly 30 years of nationwide HBV vaccination.
乙型肝炎病毒（HBV）感染与肝硬化和肝细胞癌相关。疫苗接种是旨在消除HBV感染的公共卫生政策的一个方面。在泰国实施新生儿HBV疫苗接种计划后，估计残余感染率为3.5%。然而，该研究仅在七个省份的5964名参与者中进行，且是在该活动开始仅22年后进行的。本研究旨在通过HBV监测，在更大样本量和计划实施更长时间后评估泰国的HBV血清流行率。
这是一项在泰国东北部20个省份进行的监测研究。研究期间为2010年7月至2019年11月。计算每个省份及总体的HBV血清流行率。参与者分为两组：在国家计划下接种疫苗的人和未接种疫苗的人。0至20岁的参与者作为参照，而其他年龄组（以10年为间隔）作为比较对象。通过计算每个年龄组HBV血清流行率的比值比，得出疫苗接种计划后的残余HBV血清流行率。
共有31855名受试者参与了该项目。其中，1805人（5.7%）感染了HBV。国家HBV疫苗接种组的HBV血清流行率显著低于未在国家计划下接种疫苗的组（1.0%对5.9%；p<0.001）。20岁及以下参与者的血清流行率为1.0%。31至40岁的参与者比值比最高（10.41），其次是21至30岁的参与者（7.42）。
这项实际监测研究表明，在全国范围内进行近30年的HBV疫苗接种后，残余HBV感染率为1.0%。
